Peptide B27PD (Optiquel ) as Corticosteroid-sparing Therapy for Chronic Non-infectious Uveitis (BOOTS)

Trial Profile

Peptide B27PD (Optiquel ) as Corticosteroid-sparing Therapy for Chronic Non-infectious Uveitis (BOOTS)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Nov 2015

At a glance

  • Drugs B 27PD (Primary)
  • Indications Uveitis
  • Focus Therapeutic Use
  • Acronyms BOOTS
  • Most Recent Events

    • 22 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top